Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stimolazione del nervo vago per l'artrite reumatoide da moderata a grave (RESET-RA)

13 novembre 2026 aggiornato da: SetPoint Medical Corporation

Stimolazione del nervo vago mediante il sistema SetPoint per l'artrite reumatoide da moderata a grave: lo studio RESET-RA

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Panoramica dello studio

Descrizione dettagliata

The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

243

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Mesa, Arizona, Stati Uniti, 85210
        • Arizona Arthritis ans Rheumatology Research, PPLC
      • Phoenix, Arizona, Stati Uniti, 85037
        • Arizona Arthritis Rheumatology & Research, PLLC
      • Tucson, Arizona, Stati Uniti, 85704
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Covina, California, Stati Uniti, 91722
        • Medvin Clinical Research
      • Upland, California, Stati Uniti, 91786
        • Inland Rheumatology Clinical Trials
      • Whittier, California, Stati Uniti, 90602
        • Medvin Clinical Research
    • Colorado
      • Fort Collins, Colorado, Stati Uniti, 80528
        • The Arthritis & Rheumatology Clinic of Northern Colorado
    • Connecticut
      • Stamford, Connecticut, Stati Uniti, 06905
        • Stamford Therapeutics Consortium
    • Delaware
      • Lewes, Delaware, Stati Uniti, 19958
        • Delaware Arthritis
    • Florida
      • Aventura, Florida, Stati Uniti, 33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park, Florida, Stati Uniti, 33825
        • HARAC Research Corporation
      • Boynton Beach, Florida, Stati Uniti, 33472
        • RecioMed Clinical Research Network, Inc.
      • Clearwater, Florida, Stati Uniti, 33765
        • Bay Area Rheumatology
      • Plantation, Florida, Stati Uniti, 33324
        • IRIS Research and Development
    • Georgia
      • Augusta, Georgia, Stati Uniti, 30912
        • Augusta University
      • Lawrenceville, Georgia, Stati Uniti, 30044
        • Parris and Associates Rheumatology
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern University
      • Willowbrook, Illinois, Stati Uniti, 60527
        • Willow Rheumatology and Wellness PLLC
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
    • Michigan
      • Lansing, Michigan, Stati Uniti, 48910
        • June DO, PC
    • Minnesota
      • Eagan, Minnesota, Stati Uniti, 55121
        • Saint Paul Rheumatology, P.A.
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64151
        • Kansas City Physician Partners
      • St Louis, Missouri, Stati Uniti, 63122
        • West County Rheumatology
    • Nebraska
      • Lincoln, Nebraska, Stati Uniti, 68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87102
        • Albuquerque Center for Rheumatology
    • New York
      • Babylon, New York, Stati Uniti, 11702
        • Long Island Regional Arthritis & Osteoporosis Care
    • North Carolina
      • Charleston, North Carolina, Stati Uniti, 28202
        • Arthritis & Osteoporosis Consultants Of The Carolinas
      • Charlotte, North Carolina, Stati Uniti, 28210
        • DJL Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73103
        • Health Research of Oklahoma, PLLC
      • Oklahoma City, Oklahoma, Stati Uniti, 73116
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Lehigh Valley Health Network
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • University of Pennsylvania Medical Center
    • Texas
      • Allen, Texas, Stati Uniti, 75013
        • Arthritis & Rheumatology Research Institute, PLLC
      • Austin, Texas, Stati Uniti, 78745
        • Tekton Research
      • Austin, Texas, Stati Uniti, 78717
        • Austin Regional Clinic
      • Austin, Texas, Stati Uniti, 78746
        • Central Texas Rheumatology Associates
      • Colleyville, Texas, Stati Uniti, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Houston, Texas, Stati Uniti, 77043
        • Biopharma Informatic
      • Mesquite, Texas, Stati Uniti, 75150
        • Southwest Rheumatology Research LLC
      • San Antonio, Texas, Stati Uniti, 78229
        • Clinical Trials of Texas, Inc
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22033
        • Annapolis Rheumatology
    • Washington
      • Bothell, Washington, Stati Uniti, 98021
        • Sound Clinical Research, LLC
    • West Virginia
      • Morgantown, West Virginia, Stati Uniti, 26506
        • West Virginia University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 22 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
  • Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment

Active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Altri nomi:
  • Posizionamento chirurgico dello stimolatore del nervo vago all'interno del collo

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Altri nomi:
  • Terapia di base con DMARD sintetico convenzionale

Active stimulation for 1 min once per day

Comparatore fittizio: Control

Non-active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Altri nomi:
  • Posizionamento chirurgico dello stimolatore del nervo vago all'interno del collo

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Altri nomi:
  • Terapia di base con DMARD sintetico convenzionale

Non-active stimulation for 1 min once per day

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
the American College of Rheumatology (ACR) 20 Response
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Lasso di tempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

A subject is considered having a moderate treatment response if:

  • DAS28-CRP score improvement from baseline to Week 12 is > 0.6 and ≤ 1.2, and the DAS28-CRP score at Week 12 is ≤ 5.1; or
  • DAS28-CRP score improvement from baseline to Week 12 is > 1.2, and the DAS28-CRP score at Week 12 is > 3.2.

A subject is considered having a good treatment response if:

• DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2

Week 12
DAS28-CRP Response (MCID -1.2) at Week 12
Lasso di tempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline.

DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

Week 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Lasso di tempo: Week 12

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 12
ACR20 Response at Week 12 From Day 0
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL).

Week 12

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Bone Erosion Progression, All Completers
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers With Erosive Phenotype
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Change in Erosion Score, All Completers
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers With Erosive Phenotype
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Synovitis Score, All Completers
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers With Erosive Phenotype
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Osteitis Score, All Completers
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers With Erosive Phenotype
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Lasso di tempo: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Lasso di tempo: Week 12

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 12
DAS28-CRP Low Disease Activity (LDA) or Remission
Lasso di tempo: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 12
the American College of Rheumatology (ACR) 20 Response, All Completers
Lasso di tempo: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Lasso di tempo: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Lasso di tempo: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Lasso di tempo: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Lasso di tempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Lasso di tempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Lasso di tempo: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Lasso di tempo: Week 24

Patients were asked a question about whether they would recommend the SetPoint System to family and friends

Week 24
the American College of Rheumatology (ACR) 20 Response, All Completers
Lasso di tempo: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Lasso di tempo: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Lasso di tempo: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Lasso di tempo: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
the American College of Rheumatology (ACR) 20 Response, All Completers
Lasso di tempo: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Lasso di tempo: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Lasso di tempo: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Lasso di tempo: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Lasso di tempo: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Lasso di tempo: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Lasso di tempo: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Mark Richardson, MD PhD, Massachusetts General Hospital
  • Investigatore principale: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 gennaio 2021

Completamento primario (Effettivo)

16 maggio 2024

Completamento dello studio (Stimato)

1 ottobre 2027

Date di iscrizione allo studio

Primo inviato

31 agosto 2020

Primo inviato che soddisfa i criteri di controllo qualità

31 agosto 2020

Primo Inserito (Effettivo)

7 settembre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 gennaio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

No sharing data is planned.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi